Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II gemcitabine + oxaliplatin for metastatic adenocarcinoma of unknown primary site
2005-001912-38Phase 2Active
- Sponsor
- ACROSS Group
- Start
- Oct 2005
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and oxaliplatin in occult primary adenocarcinoma, sponsored by ACROSS Group. Primary endpoint: Objective response rate. Started Oct 2005; status: active.
02
Drugs
gemcitabineoxaliplatin
03
Conditions
occult primary adenocarcinoma
Beyond the preview
Go deeper on 2005-001912-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001912-38.